A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2013
At a glance
- Drugs Pazopanib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 22 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
- 21 Jun 2012 Actual patient number (20) added as reported by ClinicalTrials.gov.
- 21 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History